COVID Pandemic leaves Private Hospitals in Financial Dire Straits

New Delhi: The already strained healthcare industry has been feeling the negative economic impact of COVID-19 with sliding bed occupancies and uncertainty of the burden of the virus. Yet, private hospitals and nursing homes, that constitute more than 60% of beds at 8.5-9 lac, 60% of inpatients and 80% of doctors in India, have been investing heavily over the past month in additional manpower, equipment, consumables and other resources to ensure 100% preparedness for safety in the healthcare facilities and eventual treatment of patients, if needed.

While the government is taking cognizance of financial strain in sectors like hospitality, tourism, construction, little is being discussed regarding the distress felt by the private healthcare sector.

Dr Sangita Reddy, President, FICCI and Joint Managing Director, Apollo Hospitals Group, said, “The private healthcare sector in India has stood beside the government firmly to contain the virus and is deeply committed to the war against COVID-19. However, there is an urgent need to consider the healthcare industry’s triple burden viz. low financial performance in pre-COVID state; sharp drop in out-patient footfalls, diagnostic testing, elective surgeries and international patients across the sector is impacting cash flow; and the increased investments due to COVID-19; which has impacted the hospitals and laboratories like never before.”

The Prime Minister‘s call to the nation to honour the healthcare professionals has indeed been a morale booster. However, with dwindling revenues, government measures in terms of liquidity infusion, tax reliefs and other waivers have become crucial for the survival of health services providers of the country.

Dr Alok Roy, Chair- FICCI Health Services Committee and Chairman, Medica Group of Hospitals, said, “The financial distress accentuated by COVID-19 lockdown has forced several standalone and small nursing homes in tier II and III cities to down the shutters. Many others are at high risk of closing down soon since their cash flows have dried up, due to steep decline in patient footfalls, and they are facing liquidity crisis for even sustaining their staff salaries.”

In view of this, FICCI in partnership with EY, carried out a study of the economic impact of COVID-19 on private healthcare sector. The report reveals that the private hospitals and laboratories, which were already facing multiple challenges, will witness an acute crisis due to COVID-19 and the subsequent lockdown, which has resulted in occupancy levels to fall to a mere 40% by late-March vis-à-vis pre-COVID occupancy levels of ~65-70%. This is expected to reduce even further. Impact on diagnostic labs is even worse, with almost 80% fall in patient visits and revenue.

Mr Kaivaan Movdawalla, Partner- Healthcare, EY India, said, “While the private sector stands fully committed to partner with the government as a national duty, it truly finds itself in a compelling situation to beseech the government for ‘differential’ financial forbearance measures and to be supported well, in order to best utilise its capabilities and capacity to serve the nation in this hour of crisis.”

FICCI-EY report recommends government support through Liquidity infusion for financing the operating losses through short term interest free/ concessional interest rate loans to address the liquidity gap to the tune of Rs 14,000 -24,000 Cr.

Although the government has issued a notification for the release of government dues under CGHS and ECHS schemes to private hospitals, which is in the range of Rs 1700-2000 crores, the payment is yet to be processed. Immediate release of such dues is crucial.

Other recommendations for providing urgent financial stimulus for the sector are:

Indirect tax reliefs/ exemptions/ waivers like- recoup amount equivalent to ineligible GST credits paid on procurements for a stipulated period; Customs duty / GST exemption on essential medicines, consumables and devices for treatment of COVID patients; Waiver or reduction of health cess on medical devices, Extension of time under the EPCG scheme etc.

Income tax benefits and deferment of statutory liability payments without interest, penalty for a stipulated period (3-6 months)

Rebate on commercial rate of power for a stipulated period

Related Posts

SSI Mantra, Made in India Robot, bats a Thousand by completing 100 Telesurgeries

Robotic Surgery Champs of India congregated @SS Innovations Headquarters in Gurgaon to script World Record Gurugram/ New Delhi: SSI Mantra, the ‘Only Made in India’ surgical robot is now like…

Swell of Footfalls for Respiratory & Cardiac Emergencies in Aakash Healthcare due to Pollution

Experts of the Multispecialty Hospital warn of the Consequences for Children and Elderly New Delhi: Pollution woes in Delhi are piling up and showing in hospitals. Swell of footfalls in…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Unnecessary use of steroid leads to risk of severe fungal infections: Doctors

Unnecessary use of steroid leads to risk of severe fungal infections: Doctors

Spurious cosmetic packaging factory busted in northwest Delhi

Spurious cosmetic packaging factory busted in northwest Delhi

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

Drugs & Cosmetics Rules | 60-Day Sample Testing Mandatory; Web-Host Reports: Bombay HC Orders Strict Action Against Erring Officers

UP plans US FDA-accredited medical device testing lab

UP plans US FDA-accredited medical device testing lab

Patent rejected for MNC’s cancer drug, generics to follow

Patent rejected for MNC’s cancer drug, generics to follow

Zydus brings world’s first Nivolumab biosimilar to India

Zydus brings world’s first Nivolumab biosimilar to India